Rising Stars in Liver Disease Landscape Discussed in MP Advisors Report Recently Published at MarketPublishers.com28 Mar 2016 • by Natalie Aster
LONDON – An unmet medical need, nonalcoholic steatohepatitis (otherwise known as NASH) is turning into a major cause of liver transplant. A meager diagnosis and absence of FDA-approved therapies represent a challenge to the design of studies of NASH.
New therapies for treatment of NASH emerge to be a burning issue for medical market players. If they will not appear in the near future, the cost to the society will be really huge.
Development of biomarkers facilitating a diagnosis, identification of populations at risk as well as assessment of disease regression or progression, and (or) a response to a treatment. This potential market may reach USD 35 billion by 2025.
At present, a large number of small companies develop drugs on their own. Besides, many large caps are expected to join the race in the upcoming years.
Topical research study “Rising Stars Outlook 2016: New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH)” developed by MP Advisors provide a comprehensive guide to the liver disease landscape, with a special focus made on NASH. The report explores unmet needs existing in this space and shed light on rising stars emerging in the marketplace. It covers the latest development in this market and throws light on some companies being active in this marketplace.
Rising Stars Outlook 2016: New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH)
Published: February, 2016
Price: US$ 2,000.00
Other diseases investigated by this publisher comprise:
More novel market research publications by our market research partner are available at MP Advisors page.